Stephen KL Chia
机构: Medical Oncology, British Columbia Cancer Agency
每年引用次数
引用次数
引用: 31,786
H-指数: 78
I10-指数 : 208
出版物: 538
The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort
SKL Chia , C Speers , A Kang , Y D’Yachkova
Proc Am Soc Clin Oncol 22 ( 6) 22 -22
107
2003
A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380-an Oral Inhibitor of HER2
PK Morrow , SL Moulder , T Baetz , S D’Aloisio
American Society of Clinical Oncologists
2
2010
A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380-an Oral Inhibitor of ErbB2
SKL Chia , T Baetz , S D’Aloisio , G Fernetich
Breast 1 5 -5
2
2009
A phase I study to assess the safety, tolerability and pharmacokinetics of ARRY-380-an oral inhibitor of HER2
SKL Chia , T Baetz , S D'Aloisio , G Fernetich
CANCER RESEARCH 69 ( 24) 802S -803S
1
2009
352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)
SA Hurvitz , SKL Chia , EM Ciruelos , X Hu
Annals of Oncology 31
2020
329P Ribociclib (RIB) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and resistance to prior endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials
SA Hurvitz , SC Lee , G Jerusalem , SA Im
Annals of Oncology 31
2020
Plaque formation by a velogenic Newcastle disease virus in human colorectal cancer cell lines.
S.-L. CHIA , W.-S. TAN , K. YUSOFF , N. SHAFEE
Acta Virologica 56 ( 4) 345 -347
5
2012
Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS)≤ 25 randomized to endocrine therapy (ET)+/-chemotherapy (CT): SWOG S1007 (RxPONDER)
Kevin M Kalinsky , William E Barlow , Julie R Gralow , Funda Meric-Bernstam
Cancer Research 82 ( 4\_Supplement) GS2 -07
2
2022
21-gene assay to inform chemotherapy benefit in node-positive breast cancer
Kevin Kalinsky , William E Barlow , Julie R Gralow , Funda Meric-Bernstam
New England Journal of Medicine 385 ( 25) 2336 -2347
206
2021
Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes
Karama Asleh , Gian Luca Negri , Sandra E Spencer Miko , Shane Colborne
Nature Communications 13 ( 1) 896
17
2022
Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.
Eleftherios P Mamounas , Hanna Bandos , Priya Rastogi , Yi Zhang
Smpte Journal
13
2021
Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.
Priya Rastogi , Hanna Bandos , Peter C Lucas , Laura van't Veer
Smpte Journal
10
2021
Abstract PD15-05: Assessment of estrogen receptor (ESR1) mRNA expression for prediction of extended aromatase inhibitor benefit in HR-positive breast cancer using NRG Oncology/NSABP B-42
Eleftherios Mamounas , Hanna Bandos , Priya Rastogi , Michael R Crager
Cancer Research 82 ( 4\_Supplement) PD15 -05
2022
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
Frankie A Holmes , Beverly Moy , Suzette Delaloge , Stephen KL Chia
European Journal of Cancer 184 48 -59
2023
Assessment of estrogen receptor (ESR1) mRNA expression for prediction of extended aromatase inhibitor benefit in HR-positive breast cancer using NRG Oncology/NSABP B-42
Eleftherios Mamounas , Hanna Bandos , Priya Rastogi , Michael R Crager
CANCER RESEARCH 82 ( 4)
2022
Proteomic analysis of breast cancer formalin-fixed paraffin-embedded clinical specimens identifies biologically-important subtypes with distinct clinical outcomes
Karama Asleh , Gian Luca Negri , Sandra E Spencer Miko , Shane Colborne
CANCER RESEARCH 81 ( 4)
2021
Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early stage breast cancer: subgroup analyses from the phase III ExteNET trial
Michael Gnant , Miguel Martin , Frankie Ann Holmes , Christian Jackisch
Proceedings of the 36th Annual Miami Breast Cancer Conference. Physicians’ Education Resource
10
2019
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin , Frankie A Holmes , Bent Ejlertsen , Suzette Delaloge
The Lancet Oncology 18 ( 12) 1688 -1700
550
2017
Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
Lillian L Siu , Ghassan Allo , Gregory R Pond , Tong Zhang
Molecular Cancer Therapeutics 10
2011
Basal Biomarkers Nestin and INPP4b Accurately Identify Intrinsic Subtype in ER Weakly-Positive Breast Cancer
Brandon S Sheffield , Karama Asleh-Aburaya , Xiuqing Wang , Dongxia Gao
LABORATORY INVESTIGATION 96 72A -72A
2016